Medomexi, 125 mg, film-coated tablets, 30 pcs.
Medomexi® is an inhibitor of free radical processes and a membrane protector. It also has antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic effects. Belongs to the class of 3-hydroxypyridines.
The mechanism of action of Medomexi® is due to its antioxidant and membrane protective effect. The drug inhibits lipid peroxidation, increases superoxidase activity, increases the lipid-protein ratio, and improves the structure and function of the cell membrane.
Medomexi® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, transport of neurotransmitters and improve synaptic transmission. Medomexi® increases dopamine levels in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria.
Increases the body's resistance to the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accidents, intoxication with ethanol and antipsychotic drugs).
In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes - phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports the activation of aerobic glycolysis that develops during acute ischemia and promotes the restoration of mitochondrial redox processes under hypoxic conditions, increases the synthesis of ATP and creatine phosphate. Ensures the integrity of the morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, increases the effectiveness of therapy, reduces the incidence of arrhythmias and intracardiac conduction disorders. Normalizes metabolic processes in ischemic myocardium, increases the antianginal activity of nitrates, improves the rheological properties of blood, reduces the consequences of reperfusion syndrome in acute coronary insufficiency.
Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis.
It has a lipid-lowering effect, reduces the content of total cholesterol and LDL.
Medomexi solution i.v. i.m. injected 50 mg/ml 5 ml amp N 5
Clinical and pharmacological group
Antioxidant drug
Release form, composition and packaging
The solution for intravenous and intramuscular administration is colorless or slightly yellowish, transparent.
| 1 ml | 1 amp. | |
| ethylmethylhydroxypyridine succinate | 50 mg | 100 mg |
Excipients: sodium disulfite (sodium metabisulfite), water for injection.
2 ml - glass ampoules (5) - contour cell packaging (1) - cardboard packs. 2 ml - glass ampoules (5) - contour cell packaging (2) - cardboard packs. 2 ml - glass ampoules (5) - contour cell packaging (20) - cardboard packs. 2 ml - glass ampoules (5) - contour cell packaging (50) - cardboard packs. 2 ml - glass ampoules (5) - contour cell packaging (100) - cardboard packs.
The solution for intravenous and intramuscular administration is colorless or slightly yellowish, transparent.
| 1 ml | 1 amp. | |
| ethylmethylhydroxypyridine succinate | 50 mg | 250 mg |
Excipients: sodium disulfite (sodium metabisulfite), water for injection.
5 ml - glass ampoules (5) - contour cell packaging (1) - cardboard packs. 5 ml - glass ampoules (5) - contour cell packaging (2) - cardboard packs. 5 ml - glass ampoules (5) - contour cell packaging (20) - cardboard packs. 5 ml - glass ampoules (5) - contour cell packaging (50) - cardboard packs. 5 ml - glass ampoules (5) - contour cell packaging (100) - cardboard packs.
pharmachologic effect
Antioxidant drug. Improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of red blood cells and platelets. It has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins.
The mechanism of action is due to its antioxidant and membrane protective effect. The drug inhibits lipid peroxidation, increases the activity of the enzyme superoxide dismutase, increases the lipid-protein ratio in the cell membrane, stabilizes blood cell membranes, reduces blood viscosity, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Increases dopamine levels in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.
It has a wide range of pharmacological activity: it increases the body’s resistance to stress, exhibits an anxiolytic effect that is not accompanied by drowsiness and a muscle relaxant effect; has nootropic properties, helps improve memory, facilitates learning processes, improves concentration and mental activity; has an anticonvulsant effect; exhibits antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol.
Pharmacokinetics
Suction and distribution
The time to reach Cmax in blood plasma with intramuscular administration is 0.3-0.58 hours. Cmax with intramuscular administration at a dose of 400-500 mg is 2.5-4 mcg/ml. Quickly distributed in organs and tissues.
Metabolism and excretion
Metabolized in the liver by glucuronidation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphatase, breaks down into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, formed in large quantities and found in urine 1-2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates.
T1/2 and the average retention time of the drug in the body with intramuscular administration is 0.7-1.3 hours. The drug is excreted in the urine mainly in the form of metabolites (50% in 12 hours) and in small quantities unchanged (0.3% in 12 h). It is most intensively excreted during the first 4 hours after administration of the drug.
Urinary excretion rates of unchanged drug and metabolites have significant individual variability.
Indications
- acute ischemic cerebrovascular accidents (as part of complex therapy);
- encephalopathy;
— vegetative-vascular dystonia;
— anxiety states in neurotic and neurosis-like conditions;
- mild cognitive impairment of vascular origin;
— age-related decline in cognitive functions in older people (disorders of memory, orientation, concentration);
— asthenic conditions, under the influence of extreme (stress) factors;
— withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
- acute intoxication with antipsychotic drugs.
Contraindications
- acute liver and/or kidney failure;
- children's age (due to lack of data);
— pregnancy (due to lack of data);
- breastfeeding period (due to lack of data);
- increased individual sensitivity to the drug.
The drug should be used with caution if you have a history of allergic diseases.
Dosage
Prescribed intramuscularly or intravenously (stream or drip). Doses are selected individually. The drug is administered slowly over 5-7 minutes in a stream, and dropwise at a rate of 40-60 drops/min. When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.
Treatment is started by prescribing the drug at a dose of 50-100 mg 1-3 times a day, gradually increasing it until a therapeutic effect is obtained. The maximum daily dose does not exceed 800 mg.
In case of acute cerebrovascular accidents, it is used in complex therapy in the first 2-4 days, 200-300 mg intravenously 1 time/day, then 100 mg intramuscularly 3 times/day. The duration of treatment is 10-14 days.
For discirculatory encephalopathy in the decompensation phase, the drug should be prescribed IV in a stream or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly at 100 mg 2-3 times a day over the next 2 weeks. For a course of prophylaxis of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days.
For mild cognitive impairment, age-related decline in cognitive function and anxiety disorders, the drug is used intramuscularly in a daily dose of 100-300 mg for 14-30 days.
For vegetative-vascular dystonia, asthenic conditions, neurotic and neurosis-like conditions - 50-400 mg/day intramuscularly for 14 days.
For alcohol withdrawal syndrome, the drug is administered in a dose of 100-200 mg IM 2-3 times a day or IV drip 1-2 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 50-300 mg/day for 7-14 days.
Side effects
With intravenous administration (especially jet): dryness of the oral mucosa, a “metallic” taste in the mouth, a feeling of “spreading warmth” throughout the body, an unpleasant odor, a sore throat and discomfort in the chest, a feeling of lack of air (usually , are associated with an excessively high rate of administration and are short-term in nature).
From the digestive system: with long-term use - nausea, flatulence.
From the side of the central nervous system: sleep disturbance (drowsiness or difficulty falling asleep).
Overdose
Symptoms: sleep disturbance (insomnia, in some cases drowsiness); with intravenous administration - a slight and short-term (up to 1.5-2 hours) increase in blood pressure.
Treatment: as a rule, not required - symptoms of sleep disturbance disappear on their own within 24 hours. In severe cases of insomnia, it is recommended to take sleeping pills. If blood pressure is excessively elevated, use antihypertensive drugs under blood pressure control.
Drug interactions
The drug Medomexi is compatible with psychotropic drugs; enhances the effect of benzodiazepine anxiolytics, antiparkinsonian drugs and carbamazepine; enhances the effect of nitrates.
special instructions
Impact on the ability to drive vehicles and operate machinery
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Pregnancy and lactation
Due to the lack of data, the use of the drug during pregnancy and lactation is contraindicated.
Use in childhood
Contraindicated in children under 1 year of age.
For impaired renal function
Contraindication: acute renal failure
For liver dysfunction
Contraindication: acute liver failure
Conditions for dispensing from pharmacies
The drug is available with a prescription.
Storage conditions and periods
List B. The drug should be stored in a place protected from light, out of reach of children, at a temperature not exceeding 25°C. Shelf life: 3 years.
Medomeksi® (MEDOMEXI)
Medomexi® is an inhibitor of free radical processes and a membrane protector. It also has antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic effects. Belongs to the class of 3-hydroxypyridines.
The mechanism of action of Medomexi® is due to its antioxidant and membrane protective effect. The drug inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, improves the structure and function of the membrane and cells. Medomexi® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Medomexi® increases dopamine levels in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria.
Increases the body's resistance to the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accidents, intoxication with ethanol and antipsychotic drugs).
In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes, phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports the activation of aerobic glycolysis that develops during acute ischemia and promotes the restoration of mitochondrial redox processes under hypoxic conditions, increases the synthesis of ATP and creatine phosphate. Ensures the integrity of the morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, increases the effectiveness of therapy, reduces the incidence of arrhythmias and intracardiac conduction disorders. Normalizes metabolic processes in ischemic myocardium, increases the antianginal activity of nitrates, improves the rheological properties of blood, reduces the consequences of reperfusion syndrome in acute coronary insufficiency. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis. Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins.
